To view Article Recommendations, you must have an active subscription.
If your access has expired, you can subscribe at $9.95 per month, the first month of your subscription will be free of charge.
If you think you should be able to access this content, please contact us.
New to F1000? See this week’s top article below for a free preview of a Recommendation.
The Biotechnology Faculty has been created by grouping relevant Sections from other F1000 Faculties, it therefore does not have separate Heads of Faculty, Section Heads or Faculty Members.
This is an important study showing that oncolytic virotherapy can be effectively combined with novel immunotherapeutic drugs targeting those immune cells that protect tumors from clearance. In this case, Newcastle disease virus (NDV) is used...
TOP RATED ARTICLE THIS WEEK [FREE TO VIEW]
6 Recommendations, most recent by| New Finding | Technical Advance
Past 7 Days
New Articles Recommended
Past 30 Days
117Articles Classified As Interesting Hypothesis8,577 total
156Articles Classified As Technical Advance16,962 total
5Articles Classified As Refutation333 total
71Articles Classified As Confirmation5,888 total
35Articles Classified As Review / Commentary1,088 total
29Articles Classified As Controversial2,277 total
349Articles Classified As New Finding33,285 total
125Articles Classified As Good for Teaching1,392 total
76Articles Classified As Novel Drug Target4,469 total
Get instant access to Article Recommendations from more than 5,000 expert scientists and clinical researchers by taking out a monthly subscription. The first month of your subscription will be free of charge.
Start your personal subscription today.Subscribe for $9.95/month
Send a recommendation to your institution's librarian or information manager to request an extended free trial for all users.Recommend to your Librarian
If you are a librarian or information manager, you may request an extended free trial for your academic or corporate institution.Request an Institutional Trial
your institution might be eligible for free access via our sponsorship scheme. Check our sponsorship page.